Diagnosis and treatment of primary myocardial disease

Incidence and clinical predictors of deep vein thrombosis in patients hospitalized with heart failure in Japan

BACKGROUND

The aim of this study was to clarify the incidence and clinical predictors of deep vein thrombosis (DVT) in patients with congestive heart failure (CHF) in Japan.

METHODS AND RESULTS

Between January 2003 and January 2008, 161 patients were admitted to Mie University Hospital with a diagnosis of CHF and underwent venous compression ultrasonography. Of them, 18 patients (11.2%) were diagnosed with DVT. As defined by New York Heart Association (NYHA) functional class, class IV patients had a higher incidence rate of DVT than those in class II or III (class II: 3 patients (4.4%), class III: 2 patients (4.8%), class IV: 13 patients (25.5%), P<0.01). Multiple logistic regression analysis identified that NYHA functional class and poor collapsibility of the inferior vena cava on ultrasonography as independent predictors of DVT (odds ratios (OR) 3.74, 95% confidence interval (CI) 1.72-8.16, P<0.01 and OR 4.43, 95%CI 1.36-14.43, P<0.05, respectively). Therapy without anticoagulation also indicated a significant increase in DVT incidence in CHF patients (OR 3.71, 95%CI 1.13-12.18, P<0.05).

CONCLUSIONS

Patients with CHF have a high risk for DVT and the risk increases according to NYHA functional class, poor IVC collapsibility or therapy without anticoagulation.

Risk of venous thromboembolism in patients hospitalized with heart failure

Because of uncertainty about the prevalence of pulmonary embolism (PE) and deep venous thrombosis (DVT) in hospitalized patients with congestive heart failure (CHF), data from the National Hospital Discharge Survey were investigated. Among hospitalized patients with CHF, PE was diagnosed in 0.73% and DVT in 1.03%. The relative risk for PE in patients with CHF compared with patients with no CHF was 2.15; for DVT, it was 1.21. The relative risk for PE in patients with CHF was greatest in patients <40 years of age (relative risk 11.72), and the relative risk for DVT was 5.46. In conclusion, a high relative risk for PE, DVT, and venous thromboembolism was shown in patients with CHF who were <60 years of age.

Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS)

It is uncertain whether anti-thrombotic treatment reduces the incidence of thrombo-embolism in patients with heart failure, so there is a need for a large scale controlled study to assess the effects of anti-thrombotic therapy in this setting. We report the design of a randomized controlled multicenter double blind trial examining the effects of aspirin, warfarin and placebo in patients with heart failure on the risk of thrombo-embolism. We planned to recruit 6000 patients with heart failure without contraindications to anticoagulants or antiplatelet agents and to follow them for a mean time of 2 years following randomization. The study was planned to determine the rate of thrombo-embolic and haemorrhagic events and death among patients randomized to aspirin, warfarin and placebo, stratified according to the presence or absence of underlying coronary disease. Ancillary studies parallel to the main study will attempt to identify clinical and echocardiographic risk factors for thrombo-embolism and will also examine whether hemostatic or neurohormonal mechanisms contribute to an increase in the risk of thrombo-embolism in patients with heart failure. We hoped that the results of the study would improve the clinical management and cost-effectiveness of treatment for patients with heart failure. However, the recruitment of patients proved more difficult than expected and a number of centers decided not to participate. To avoid a great delay it was decided by the principal investigators and submitted to the executive committee to terminate enrolment in this study when 300 patients had been enrolled, and accept that this is a pilot study.

Immunosuppressive therapy in inflammatory myocarditis: long-term follow-up

Sixteen patients (12 male and 4 female, age 2-46 years) with endomyocardial biopsy-proven myocarditis were prospectively evaluated with immunosuppressive therapy including azathioprine and prednisolone in addition to other standard measures. Patients were either in NYHA class IV (n = 12) or class III (n = 4). Twelve patients showed improvement and the remaining 4 continued to deteriorate: 2 died at 1 and 2 months after therapy and the other 2 were lost to follow-up after 4-6 weeks of therapy. Three of the 12 patients who showed significant improvement, after sudden omission of therapy (at 8 weeks, 6 and 8 months) worsened and died. One patient who showed significant improvement died suddenly after 9 months of therapy while playing football. The remaining patients have shown significant clinical and haemodynamic improvement with normalization of myocardial morphology. Serial haemodynamic studies revealed a significant fall in cardiothoracic ratio (before: 62.3 +/- 4.7%; 3 months: 55.1 +/- 3.1%, P less than 0.0001; 6-12 months: 50.6 +/- 1.5%, P less than 0.0001), mean pulmonary artery pressure (before: 34.3 +/- 13.05 mm; 3 months: 20.4 +/- 8.71 mm, P less than 0.01; 6-12 months: 20.0 +/- 2.75 mm, P less than 0.01) and mean pulmonary artery wedge pressure (before: 26.0 +/- 9.07 mm; 3 months 14.0 +/- 5.63 mm, P less than 0.001; 6-12 months: 13.2 +/- 4.57 mm, P less than 0.001). The left ventricular ejection fraction improved from 24.3 +/- 8.36% to 35.8 +/- 9.72% (P less than 0.001) at 3 months and 49.8 +/- 18.2% (P less than 0.0001) at 6-12 months of therapy. Two patients have been subsequently lost to follow-up whereas the remaining 6 patients are on follow-up for 1-4 years after therapy and are doing fine. Our uncontrolled observations suggest that immunosuppressive therapy may be useful in patients with inflammatory myocarditis.

Factors affecting tolerance to digitalis

A review of factors altering the safety margin between a therapeutic and a toxic dose of digitalis includes the consideration of: clinical conditions to which digitalis action may be undesirable, allergy and hypersensitivity to digitalis, physiologic factors modifying tolerance to digitalis, factors that change the amount of digitalis in the body, nervous and metabolic factors modifying tolerance to digitalis, modifications of digitalis tolerance produced by the status of the myocardium, and modifications of digitalis tolerance produced by diseases of other organs. The problems related to digitalis toxicity are more common than those of resistance to treatment. The most important factors contributing to decreased tolerance and risk of toxicity are: heart disease, poor renal function, hypokalemia and hypothyroidism. The roles of impaired liver function, chronic lung disease, acid-base disturbances, anesthesia, autonomic imbalance, calcium and magnesium are less important and less well established.

Prognosis and treatment of cardiomyopathy and myocarditis

Dilated cardiomyopathy is a heterogeneous group of disorders with a prognosis that is dependent upon the severity of presenting clinical and hemodynamic abnormalities. Although this condition is characterized by a high mortality, spontaneous improvement is noted in 25% of cases. Standard therapeutic modalities are nonspecific and consist of the therapy of congestive heart failure and ventricular arrhythmia. Recent studies suggest that beta blockade and cardiac transplantation may soon become accepted modalities in this condition. Acute viral myocarditis is a common disease that has a good prognosis, however occasionally progression to chronic myocardial disease has been identified. The therapy of acute viral myocarditis should be limited to symptomatic treatment, anti-coagulation, and bed rest. When chronic myocarditis is identified on endomyocardial biopsy in patients with heart failure of unknown cause, the treatment differs little from that of dilated cardiomyopathy with the exception that recognizing that efficacy has not been proven; immunosuppressive therapy may be added in life-threatening situations. Future studies will be directed at further clarification of the prognosis of each of these conditions with intensive evaluation of the role of beta blockade and immunosuppression.

Diagnosis and management of acute myocarditis aided by serial myocardial biopsy

Two cases in which right ventricular endomyocardial biopsy established a definitive pathologic diagnosis of acute myocarditis are presented. Both patients presented with severe left ventricular dysfunction, atrial flutter and an intraventricular conduction defect. Immunofluorescent and immunoperoxidase examination of the biopsy specimens suggested a humoral immune mechanism in one case and a cell-mediated immune mechanism in the other. Substantial improvement in cardiac function followed treatment with prednisolone and azathioprine in both cases. Significant regression of the myocardial inflammatory changes was documented by a further endomyocardial biopsy in each case following clinical improvement.

Myocarditis and cardiomyopathy

With more widespread application of EMB techniques, a significant percentage of ICCM patients have been found to have lymphocytic myocarditis on biopsy. It is now appreciated that patients with myocarditis may also present with isolated abnormalities of left ventricular diastolic function, dysrhythmias, and/or complaints of chest discomfort with normal coronary angiograms. Epidemiologic and serologic data incriminate a viral etiology underlying many cases of acute myocarditis and ICCM. Although most cases of viral myocarditis appear to resolve without residual left ventricular dysfunction, a small but significant percentage of these patients progress to chronic congestive cardiomyopathy. In the absence of persistent active viral infection in these patients, myocardial damage may be mediated by both cellular and humoral immune mechanisms. The concept of virus-induced immune mediated myocardial damage forms the basis for attempts at immunosuppressive therapy. Whether immunosuppressive therapy alters the natural history of myocarditis is at present unknown and awaits demonstration by a controlled clinical trial.

Primary myocardial disease. Correlation with clinical findings, angiographic and biopsy diagnosis. Follow-up of 139 patients

The purpose of this study was determination of the prognostic value of clinical and tissue (biopsy) findings of 139 patients with cardiomyopathy. The types of cardiomyopathy were congestive (113 patients) and hypertrophic or constrictive (26 patients). The mean follow-up period of all patients was 4.3 years. Follow-up of the survivors was between 13 months and 11.9 years, mean 5.4 years. Of the 47 cardiac deaths (33.8%), the minimum and maximum follow-up was two weeks and 7.5 years, respectively (mean 2.1 years). Patients with congestive heart failure had the highest five year cardiac mortality rate (51.8%). Coexisting cardiac arrhythmia had no influence on prognosis and an arrhythmia only was benign in most patients. Myocardial hypertrophy or fibrosis or both and myocardium with no pathologic diagnosis had prognostic value. Small-vessel disease was infrequent and not associated with specific clinical manifestations.

Saddle embolism of the innominate artery

A case of saddle embolism to the innominate artery in a patient with congestive myocardiopathy is presented. Embolectomy was successfully performed under local anesthesia using a combined carotid and axillary approach.

The clinical course of primary myocardial disease in infants and children

A total of 161 infants and children, ranging in age from 1 day to 17 years at initial encounter (mean, 3.7 years), was seen over a 30 year period with primary myocardial disease (idiopathic myocarditis, nonobstructive cardiomyopathy, endocardial fibroelastosis, and an anatomically unknown category). These patients were observed from 1 hour to 23 years after initial encounter and cardiac disease has resolved in 27 per cent, resulted in death in 35 per cent, and continues in 38 per cent. The majority were first referred to us with congestive heart failure; all exhibited ST-T changes and cardiomegaly, 67 of 150 had left ventricular hypertrophy, 23 of 151 arrhythmias, and 55 of 153 pulmonary vascular congestion. Initial ventricular depolarization abnormalities were very frequent. Significant clinical predictors of fatal outcome included pulmonary vascular congestion, "northwest" axis deviation, and a cardiac index less than three L./min./M.2. Death occurred during the first year after initial encounter in 44 of 57 who died, and in all 13 with proved myocarditis. Primary myocardial disease is a serious disease of infancy and childhood, resulting in death or residual cardiac disease in three fourths of those affected.

[Autoantibodies against heartmuscle sarcolemma in sera of patients with an idiopathic cardiomyopathy (author's transl)]

68 patients with clinical and hemodynamical diagnosis of idiopathic cardiomyopathy (CM) were analysed for antibody in their sera using an immunofluorescence sandwich technique after titration of the sera in tissue sections. 60 of these patients had antibodies against heart muscle sarcolemma with titers up to 1:64. Out of these, the antibodies in 9 sera could be absorbed with group A streptococci. The antibodies reacted in no case with striated or smooth muscle sarcolemma. The 25 patients with an obstructive type of CM showed the highest titers and 12 of them, in addition, had antinuclear factors in their sera. These findings suggested an auto-allergic etiology for most cases of idiopathic CM.